ResearcherCtr For Molecular Medicine/ImmunologyNo recent work listed
David V. Gold
Matched on OpenAlex author ID A5108410851; NIH RePORTER profile ID 1941804. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 14
2012: 1 paper · 2013: 3 papers · 2014: 1 paper, 1 grant · 2015: 1 paper
Papers 6
- Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer. Co-author DOI 10.18632/oncotarget.2760↗
- Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. Last author DOI 10.5858/arpa.2013-0056-oa↗
- PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.27762↗
- Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Co-author DOI 10.1186/1476-4598-12-143↗
- Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma. Co-author PMID 24228110↗
- Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Co-author DOI 10.1002/cncr.27592↗
Grants 1
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- David M. Goldenberg · 5 shared papers, 2012–2015 · strength 0.24
- Paper Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for panc… DOI 10.18632/oncotarget.2760↗
- Paper Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. DOI 10.5858/arpa.2013-0056-oa↗
- Paper Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic duc… DOI 10.1186/1476-4598-12-143↗
- Donglin Liu · 2 shared papers, 2013–2015 · strength 0.12
- Paper Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for panc… DOI 10.18632/oncotarget.2760↗
- Paper Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic duc… DOI 10.1186/1476-4598-12-143↗
- Chanjuan Shi · 2 shared papers, 2013–2014 · strength 0.10
- Nipun B. Merchant · 2 shared papers, 2013–2014 · strength 0.10
- Sabrina C. Sopha · 1 shared paper, 2013 · strength 0.04
- Β. Michael Ghadimi · 1 shared paper, 2013 · strength 0.04
- Jochen Gaedcke · 1 shared paper, 2013 · strength 0.04
- Michael Goggins · 1 shared paper, 2013 · strength 0.04
- Ralph H. Hruban · 1 shared paper, 2013 · strength 0.04
- Bert H. O’Neil · 1 shared paper, 2012 · strength 0.02
- Seza Güleç · 1 shared paper, 2012 · strength 0.02
- Alberto J. Montero · 1 shared paper, 2012 · strength 0.02
- Allyson J. Ocean · 1 shared paper, 2012 · strength 0.02
- Tanios Bekaii‐Saab · 1 shared paper, 2012 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.